名稱 | Human ADORA3 Ga15/CHO |
型號 | CBP71338 |
報價 | ![]() |
特點(diǎn) | Human ADORA3 Ga15/CHO 凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 【連載-企業(yè)參考品】 急性淋巴細(xì)胞白血病的診斷參考品的選擇
- *針對肝癌的PD-1抗體獲FDA批準(zhǔn),國產(chǎn)PD-1抗體進(jìn)入三期
- Nature子刊:重磅級研究或?qū)㈤_啟人類長生不老的神話!
- 慢病毒整合位點(diǎn)標(biāo)準(zhǔn)品強(qiáng)勢來襲
- FLT3標(biāo)準(zhǔn)品簡介
- BRCA1/BRCA2基因檢測標(biāo)準(zhǔn)品
- 認(rèn)識一下北京細(xì)胞庫的檢測項(xiàng)目
- 可視化觀察黑色素瘤早期轉(zhuǎn)移,鑒定出一種新的治療靶標(biāo)
- ATCC細(xì)胞如何培養(yǎng)?
- AKT E17K突變抑制劑細(xì)胞篩選模型介紹
聯(lián)系我們
電話:4008750250
號碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > GPCR細(xì)胞株 > CBP71338Human ADORA3 Ga15/CHO

- 詳細(xì)內(nèi)容
CBP71338 | |
I. Background | |
Extracellular adenosine mediates a multitude of biological effects, including wakefulness, antiarrythmia, bronchoconstriction and response to ischemia and oxidative stress. A family of four G-protein coupled adrenoceptors, A1, A2A, A2B and A3, is responsible for these effects. A3, which couples to Gi/o, is expressed in a wide range of human tissues, but most predominantly in the lung and liver. Recent animal model studies have shown that A3 receptors play important roles in brain ischemia, immunosuppresion, and bronchospasm. A3 receptor agonists and/or agonists may have important clinical value in the treatment of asthma and inflammation. Mice lacking A3 receptors display reduced mast cell degranulation and bronchoconstriction in response to adenosine. | |
II. Introduction | |
Host Cell: | CHO |
Stability: | 20 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | F12K+10% FBS+2 μg/ml puromycin+ 100 μg/ml Hygromycin B |
Mycoplasma Status: | Negative |
Storage: | Liquid nitrogen immediately upon delivery |
Application(s): | Functional assays for ADORA3 receptor |
Transducer: | Gi |
Ⅲ. Description of Host Cell Line | |
Organism: | Hamster |
Tissue: | Ovary |
Morphology: | Epithelial |
Growth Properties: | Adherent |
Ⅳ. Representative Data |